Future Outlook of the Retinoblastoma Treatment Market: Growth, Trends, and Emerging Opportunities Explored
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the retinoblastoma treatment market grown over the years?
The market size for treating retinoblastoma has demonstrated robust growth in the past few years. From $2.03 billion in 2024, it’s anticipated to expand to $2.16 billion in 2025, marking a compound annual growth rate (CAGR) of 6.2%. Factors contributing to growth during the historic period include an uptick in funding, the potential for retinoblastoma to recur, early detection and treatment, heightening awareness about various cancer types, and significant progress in cancer research.
What Is the forecasted market size and growth rate for the retinoblastoma treatment market?
The retinoblastoma treatment market size is expected to see strong growth in the next few years. It will grow to $2.7 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to increasing demand for ophthalmic treatment and surgeries, increasing incidence of retinoblastoma, increasing research and development activities, growing awareness pertaining to retinoblastoma treatment, increasing healthcare expenditure. Major trends in the forecast period include advancements in medical technology, improved diagnostic capabilities, augmented investments in pediatric oncology, new product approval, improvements in medical infrastructure.
Get your retinoblastoma treatment market report here!
https://www.thebusinessresearchcompany.com/report/retinoblastoma-treatment-global-market-report
What are the major factors driving growth in the retinoblastoma treatment market?
The surge in demand for procedures and treatments related to eye care and surgery is expected to boost the retinoblastoma treatment market’s progression. Treatments for eye-related conditions involve medical processes to detect, treat, and rectify diseases affecting the eyes and vision. The increase in these treatments can be attributed to an aging populace, an increased occurrence of conditions such as cataracts and age-related macular degeneration, advancements in technology for better and more accessible treatment options, and increasing awareness leading to early detection and intervention. Treatment for retinoblastoma, a cancerous growth within the eye(s), becomes imperative during eye surgeries to avoid metastasis or recurrence while preserving vision and eye functionality. For instance, in September 2023, a report from the Office for Health Improvement and Disparities, a UK government unit, revealed that there were over 4.09 million cataract surgery admissions in England, corresponding to a rate of 3,803 (3,789 to 3,816) per 100,000 population in the financial year ending 2022. Also, during the same period, over 10,900 admissions for rhegmatogenous retinal detachment surgeries and over 677,000 intravitreal injection therapy procedures were reported, with rates of 23.4 (22.9 to 24.0) and 4,796 (4,769 to 4,823) per 100,000 population, respectively. Thus, the rising demand for eye treatment and surgeries contributes to the growth of the retinoblastoma treatment market.
What key areas define the segmentation of the global retinoblastoma treatment Market?
The retinoblastoma treatment market covered in this report is segmented –
1) By Type: Non-Hereditary Retinoblastoma, Hereditary Retinoblastoma
2) By Treatment Type: Surgery, Radiation Therapy, Laser Therapy (Photocoagulation), Cryotherapy, Thermotherapy, Chemotherapy, Ophthalmic Artery Infusion Chemotherapy, High-Dose Chemotherapy And Stem Cell Transplant
3) By Disease Stage: Intraocular Retinoblastoma, Extraocular Retinoblastoma
4) By Application: Hospitals, Cancer Institutes, Other Applications
Subsegments:
1) By Non-Hereditary Retinoblastoma: Unilateral Non-Hereditary Retinoblastoma, Bilateral Non-Hereditary Retinoblastoma
2) By Hereditary Retinoblastoma: Bilateral Hereditary Retinoblastoma, Unilateral Hereditary Retinoblastoma
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15664&type=smp
What are the top market players propelling the growth of the retinoblastoma treatment industry?
Major companies operating in the retinoblastoma treatment market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Otsuka Pharmaceutical, Daiichi Sankyo Company, Taiho Pharmaceutical Co. Ltd., Icon Bioscience Inc., Ono Pharmaceutical Co. Ltd., Nippon Shinyaku Co. Ltd., Cadila Pharmaceuticals, Arcus Biosciences Inc., Sheba Medical Center, Cellceutix Corporation, Phio Pharmaceuticals Inc.
What are the key trends shaping the future of the retinoblastoma treatment market?
Leading firms in the retinoblastoma treatment field are devising innovative strategies like oncolytic adenovirus to improve service to clients with more advanced features. Oncolytic adenovirus, a virus genetically modified to target and destroy cancer cells while sparing healthy ones, exemplifies such innovation. In a notable development in February 2022, VCN Biosciences, a Spanish biotech firm, earned the orphan drug designation from the U.S. Food and Drug Administration for its product VCN-01. This specially designed oncolytic adenovirus is earmarked for treating retinoblastoma and is currently under clinical trial for its potential against incurable cancers like pancreatic carcinoma. VCN-01 has already been tested in four phase 1 clinical trials and is being viewed as a possible standalone treatment for retinoblastoma patients who have not responded to chemotherapy. Its intravitreal administration has brought about total remission and tumour shrinkage in several patients, establishing its qualifications for the approved orphan drug designation.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15664
What regions are contributing significantly to the growth of the retinoblastoma treatment market?
North America was the largest region in the retinoblastoma treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinoblastoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Gastrointestinal Bleeding Treatment Devices Global Market Report 2024
Industrial Water Treatment Chemicals Global Market Report 2024
Alzheimer’s Disease Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
